The deal includes Softgel’s softgel, squeeze tube and tincture manufacturing facility that specializes in encapsulation of human and pet nutrition products. The Softgel facility is able to produce over one million softgels per shift, according to a press release about the deal, and will be taking immediate steps to double its capacity to meet the demand from Bioriginal.

Bioriginal describes the acquisition as a natural step in the company’s growth and provides security of supply and responsible manufacturing around the globe.

The terms of the transaction have not been disclosed as the companies are privately owned.

“Thanks to the support of our clients and partners, we are fortunate to be in a position where we can expand with industry leaders, like Softgel,” said Shannon Sears, President and CEO of Bioriginal, a wholly owned subsidiary of Cooke Inc.

“The addition of Softgel expands Bioriginal’s global supply abilities, removing the need to outsource softgel production, improving production efficiencies, and enhancing supply chain management. This level of vertical integration ensures what is on the label is in the bottle. Consumers deserve that level of confidence.”

On the acquisition trail ​

Softgel is the fourth business Bioriginal has acquired in 2023. Earlier this year the organization purchased the Factory, a pet treat manufacturing facility in the Netherlands; Kroppenstedter Ölmühle, a plant-based oil processing facility with 101 years of experience in Germany; and Cana Corp., a trading corporation in Yokohama, Japan that has since been rebranded as Bioriginal Asia.

Bioriginal now operates seven manufacturing facilities on two continents, including offices in Canada, the USA, the Netherlands, Germany, and Japan, supported by 18 warehouses around the globe.